Sihuan Pharmaceutical Holdings Group ( (HK:0460) ) has shared an announcement.
Sihuan Pharmaceutical Holdings Group Ltd. announced a voluntary share repurchase plan, buying back 15 million shares at an average price of HK$0.5836 per share, totaling approximately HK$8.75 million. This move is part of the company’s strategy to enhance shareholder value and reflects its confidence in its future growth, driven by significant advancements in its medical aesthetics and innovative pharmaceuticals segments. The company reported a 65.4% year-on-year increase in revenue from its medical aesthetics business, and it has received approval for 21 new drugs in 2024, which are expected to boost future revenue and profit.
More about Sihuan Pharmaceutical Holdings Group
Founded in 2001 and listed on the Main Board of the Stock Exchange in 2010, Sihuan Pharmaceutical is an international medical aesthetics and biopharmaceutical company. It focuses on innovation with a strong research and development platform, a diverse global product pipeline, and a comprehensive sales system. The company aims to lead in the medical aesthetics and biopharmaceutical sectors in China.
Technical Sentiment Signal: Strong Buy
Current Market Cap: $792.3M
For a thorough assessment of 0460 stock, go to TipRanks’ Stock Analysis page.